Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Instagram Outage Disrupts Thousands of U.S. Users 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Fort Lauderdale, Fla., March 19, 2018 -- CTI Clinical Trial & Consulting Services (CTI), a full-service, contract research organization (CRO) specializing in Early Phase, rare disease clinical trials, has expanded its existing partnership with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of patient-centric, clinical data management technology. Under the terms of a new multi-year, multi-million dollar agreement, CTI will use TrialMaster electronic data capture (EDC) solutions for studies during a four-year period. CTI conducts a high volume of diverse, complex and technically challenging studies around the globe.
“We’re excited to continue building our partnership with OmniComm,” said Todd Bonta, director of Clinical Data Management at CTI. “We have had a history of success with OmniComm’s TrialMaster suite, and we look forward to continuing to offer our sponsors the unique benefits provided by OmniComm’s solutions.”
OmniComm was selected for the partnership based on its EDC solutions, which offer inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important to CTI. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process.
“OmniComm has been a valuable and flexible partner, helping CTI build a powerful suite of solutions for our Clinical Operations department,” said Louis Minham, senior director, Information Technologies at CTI. “We are happy to continue to partner with OmniComm as they expand their TrialMaster suite.”
Under the terms of the agreement, CTI will use TrialMaster, TriaIBuilder®, TriaIExplorer® AdHoc reporting, AutoEncoder®, OmniConnect, LabLoading and eLearning.
“Not only are we very proud of our established relationship with CTI, but also that we have earned their trust for increased business and commitment,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “It is a pleasure to work with a company that shares the same level of passion for problem solving for clients and seeks robust, scalable and innovative solutions to help meet expectations.”
About CTI Clinical Trial & Consulting Services
CTI Clinical Trial & Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization, including real world evidence. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hematology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across six continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. Please visit http://ctifacts.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems provides a critical role in enhancing patient lives by shortening time to market of
essential life-saving treatments. OmniComm Systems is dedicated to providing the latest eClinical technology enabling the world’s life science organizations to maximize the value of their clinical research investments. OmniComm’s solutions provide better trial oversight and study delivery, connecting patients to better healthcare. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 [email protected]
